172 related articles for article (PubMed ID: 38627450)
1. Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity.
Liang EC; Rejeski K; Fei T; Albittar A; Huang JJ; Portuguese AJ; Wu Q; Raj S; Subklewe M; Shouval R; Gauthier J
Bone Marrow Transplant; 2024 Apr; ():. PubMed ID: 38627450
[TBL] [Abstract][Full Text] [Related]
2. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
Rejeski K; Subklewe M; Aljurf M; Bachy E; Balduzzi A; Barba P; Bruno B; Benjamin R; Carrabba MG; Chabannon C; Ciceri F; Corradini P; Delgado J; Di Blasi R; Greco R; Houot R; Iacoboni G; Jäger U; Kersten MJ; Mielke S; Nagler A; Onida F; Peric Z; Roddie C; Ruggeri A; Sánchez-Guijo F; Sánchez-Ortega I; Schneidawind D; Schubert ML; Snowden JA; Thieblemont C; Topp M; Zinzani PL; Gribben JG; Bonini C; Sureda A; Yakoub-Agha I
Blood; 2023 Sep; 142(10):865-877. PubMed ID: 37300386
[TBL] [Abstract][Full Text] [Related]
3. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K; Wang Y; Hansen DK; Iacoboni G; Bachy E; Bansal R; Penack O; Müller F; Bethge W; Munoz J; Mohty R; Bücklein VL; Barba P; Locke FL; Lin Y; Jain MD; Subklewe M
Blood Adv; 2024 Apr; 8(8):1857-1868. PubMed ID: 38181508
[TBL] [Abstract][Full Text] [Related]
4. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA.
Rejeski K; Greco R; Onida F; Sánchez-Ortega I; Bonini C; Sureda A; Gribben JG; Yakoub-Agha I; Subklewe M
Hemasphere; 2023 May; 7(5):e889. PubMed ID: 37125259
[TBL] [Abstract][Full Text] [Related]
5. Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K; Subklewe M; Locke FL
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
[TBL] [Abstract][Full Text] [Related]
6. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
Hayden PJ; Roddie C; Bader P; Basak GW; Bonig H; Bonini C; Chabannon C; Ciceri F; Corbacioglu S; Ellard R; Sanchez-Guijo F; Jäger U; Hildebrandt M; Hudecek M; Kersten MJ; Köhl U; Kuball J; Mielke S; Mohty M; Murray J; Nagler A; Rees J; Rioufol C; Saccardi R; Snowden JA; Styczynski J; Subklewe M; Thieblemont C; Topp M; Ispizua ÁU; Chen D; Vrhovac R; Gribben JG; Kröger N; Einsele H; Yakoub-Agha I
Ann Oncol; 2022 Mar; 33(3):259-275. PubMed ID: 34923107
[TBL] [Abstract][Full Text] [Related]
7. How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy.
Davis JA; McGann M; Marini J; Hashmi H
Expert Rev Anticancer Ther; 2024 Apr; ():1-4. PubMed ID: 38626305
[No Abstract] [Full Text] [Related]
8. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Transplant Cell Ther; 2024 Apr; 30(4):404-414. PubMed ID: 38281589
[TBL] [Abstract][Full Text] [Related]
9. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management.
Rejeski K; Jain MD; Shah NN; Perales MA; Subklewe M
Lancet Haematol; 2024 May; ():. PubMed ID: 38734026
[TBL] [Abstract][Full Text] [Related]
10. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
[TBL] [Abstract][Full Text] [Related]
11. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
[TBL] [Abstract][Full Text] [Related]
12. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
13. The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy.
Wang Y; Song Z; Geng Y; Gao L; Xu L; Tang G; Ni X; Chen L; Chen J; Wang T; Fu W; Feng D; Yu X; Wang L; Yang J
Front Oncol; 2022; 12():987965. PubMed ID: 36249041
[TBL] [Abstract][Full Text] [Related]
14. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
15. INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities.
McNerney KO; Hsieh EM; Shalabi H; Epperly R; Wolters PL; Hill JA; Gardner R; Talleur AC; Shah NN; Rossoff J
Transplant Cell Ther; 2024 Jan; 30(1):38-55. PubMed ID: 37821079
[TBL] [Abstract][Full Text] [Related]
16. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
Kansagra AJ; Frey NV; Bar M; Laetsch TW; Carpenter PA; Savani BN; Heslop HE; Bollard CM; Komanduri KV; Gastineau DA; Chabannon C; Perales MA; Hudecek M; Aljurf M; Andritsos L; Barrett JA; Bachanova V; Bonini C; Ghobadi A; Gill SI; Hill JA; Kenderian S; Kebriaei P; Nagler A; Maloney D; Liu HD; Shah NN; Kharfan-Dabaja MA; Shpall EJ; Mufti GJ; Johnston L; Jacoby E; Bazarbachi A; DiPersio JF; Pavletic SZ; Porter DL; Grupp SA; Sadelain M; Litzow MR; Mohty M; Hashmi SK
Bone Marrow Transplant; 2019 Nov; 54(11):1868-1880. PubMed ID: 31092900
[TBL] [Abstract][Full Text] [Related]
17. The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities.
Ellard R; Kenyon M; Hutt D; Aerts E; de Ruijter M; Chabannon C; Mohty M; Montoto S; Wallhult E; Murray J
Clin Hematol Int; 2022 Sep; 4(3):75-88. PubMed ID: 36131128
[TBL] [Abstract][Full Text] [Related]
18. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
19. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
Nikiforow S; Frigault MJ; Frey NV; Gardner RA; Komanduri KV; Perales MA; Kebriaei P; Warkentin PI; Pasquini M; Aho JL; Levine BL; Heslop HE; Hlucky TL; Habucky K; Gharibo M; Jagasia M; Locke FL
Transplant Cell Ther; 2023 Apr; 29(4):228-239. PubMed ID: 36709800
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?
Sun T; Li D; Huang L; Zhu X
Front Immunol; 2023; 14():1141779. PubMed ID: 37223096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
